Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Clinical trial NCT04486833 · RECRUITING

Trial details

NCT number: NCT04486833
Sponsor: Genprex, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small Cell Lung

Start date: 2021-09-03
Primary completion: 2028-03-01
Enrollment: 158

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.